Objective: Around 50% of depressed patients do not respond to antidepressants. Evidence from familial studies suggests a genetic component to this. This study investigated whether patients with polymorphisms in genes related to the hypothalamic-pituitary-adrenal (HPA) axis were less likely to respond to antidepressants. Method: EMBASE, MEDLINE, PsycINFO, and the Cochrane Library were searched. Inclusionary criteria were: 1) patients with depression, 2) study of HPA axis-related candidate genes, 3) at least four weeks of antidepressants, and 4) assessment of depressive symptoms dividing patients into non-responders and responders. Results: Nineteen studies were identified. Non-responders and responders did not differ in single nucleoti...
Background: Antidepressants are a first-line treatment for depression. However, only a third of indi...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do ...
Objective: Around 50% of depressed patients do not respond to antidepressants. Evidence from familia...
Artículo de publicación ISIBackground: Increased cortisol levels and genetic polymorphisms have been...
The hypothalamic-pituitary-adrenal (HPA) axis plays a primary role in stress response through the re...
Objective: Genetic variation within the hypothalamic-pituitary-adrenal (HPA) axis has been linked to...
There is currently a gap between what is known about genetic susceptibility to depression and how th...
Objective: There is overwhelming evidence that activation of the hypothalamic-pituitary-adrenal (HPA...
Major depression is a stress-related disorder with robust clinical and preclinical data implicating ...
Background: It has been suggested that outcomes of antidepressant treatment for major depressive dis...
Depression is one of the most prevalent diseases worldwide, afflicting approximately 17 million adul...
Genetic variation underlying hypothalamic pituitary adrenal (HPA) axis over-activity in healthy cont...
Depression is one of the most common diseases worldwide with over 300 million people currently diagn...
Antidepressants are often only moderately successful in decreasing the severity of depressive sympto...
Background: Antidepressants are a first-line treatment for depression. However, only a third of indi...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do ...
Objective: Around 50% of depressed patients do not respond to antidepressants. Evidence from familia...
Artículo de publicación ISIBackground: Increased cortisol levels and genetic polymorphisms have been...
The hypothalamic-pituitary-adrenal (HPA) axis plays a primary role in stress response through the re...
Objective: Genetic variation within the hypothalamic-pituitary-adrenal (HPA) axis has been linked to...
There is currently a gap between what is known about genetic susceptibility to depression and how th...
Objective: There is overwhelming evidence that activation of the hypothalamic-pituitary-adrenal (HPA...
Major depression is a stress-related disorder with robust clinical and preclinical data implicating ...
Background: It has been suggested that outcomes of antidepressant treatment for major depressive dis...
Depression is one of the most prevalent diseases worldwide, afflicting approximately 17 million adul...
Genetic variation underlying hypothalamic pituitary adrenal (HPA) axis over-activity in healthy cont...
Depression is one of the most common diseases worldwide with over 300 million people currently diagn...
Antidepressants are often only moderately successful in decreasing the severity of depressive sympto...
Background: Antidepressants are a first-line treatment for depression. However, only a third of indi...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do ...